Conditions: Central Centrifugal Cicatricial Alopecia
Keywords: Central centrifugal cicatricial alopecia open-label pilot study
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 20
Healthy volunteers: no

Brief summary:
This is a single-center, open-label clinical study to study the efficacy of apremilast in the treatment of mild to moderate central centrifugal cicatricial alopecia. The investigators hypothesize that the anti-inflammatory properties of apremilast may play a role in the decreasing scalp inflammation in patients with CCCA and may prevent further hair loss and potentially induce hair regrowth in patients with mild to moderate disease.

Detailed description:
Central centrifugal cicatricial alopecia (CCCA) is a type of scarring alopecia commonly seen in women of African American descent. The etiology is not completely understood, but CCCA likely results from a combination of hair-grooming practices, a pro-inflammatory state within the hair follicles, and genetic factors. The management of CCCA remains a challenge as there are no published treatment guidelines. Current therapies aim to decrease inflammation in order to prevent further hair loss.

Apremilast, an oral phosphodiesterase-4 inhibitor, has been shown to be effective in the treatment of moderate to severe plaque psoriasis and psoriatic arthropathy. In vitro studies have demonstrated anti-inflammatory properties via inhibition of inflammatory mediators. Therefore, apremilast offers a possible therapeutic option for CCCA. This will be a single-center, open-label clinical study to determine the efficacy of apremilast in the treatment of mild to moderate central centrifugal cicatricial alopecia.

Arms:
arm 1: Patients with CCCA

Interventions: intervention 1: Apremilast
Intervention descriptions: intervention 1: 30 mg BID

Protocol document:
Prot_000.pdf: 
 
 
 
 
An Open-label Pilot Study to Investigate the Efficacy of Apremilast in the Treatment of Central 
Centrifugal Cicatricial Alopecia (CCCA) 
PI: Saakshi Khattri, MD 
NCT03521687 
Document Date: 02-01-2021 
 
 


Protocol Document for 17-01126 
Principal Investigator: Saakshi Khattri, M.D. 
Mount Sinai  
 
Brief Summary of Research (250-400 words):  
Central centrifugal cicatricial alopecia (CCCA) is a type of scarring alopecia commonly seen in women of 
African American descent. Clinically, hair loss starts at the vertex of the scalp and progresses 
circumferentially. The etiology is incompletely understood, but likely results from a combination of hair-
grooming practices, a pro-inflammatory state within the hair follicles, and genetic factors. 
This will be a single-center, open-label clinical study to determine the efficacy of apremilast in the treatment 
of mild to moderate central centrifugal cicatricial alopecia.  A total of 20 subjects (ages 18 years and older, 
female, CHLG <4) are expected to complete this study, which will run for a total of up to 30 weeks. 
The study consists of two periods: Screening (from 1 to 4 weeks); Open label treatment period (24 
weeks). Follow-up for suture removal will occur 2 weeks after discontinuation only in patients who have 
undergone punch biopsy. Those who meet all of the inclusion/exclusion criteria and are enrolled in the 
study will receive apremilast for the entire treatment period. 
 
Objectives 
The purpose of this study is to evaluate the efficacy of apremilast in the treatment of mild to moderate 
CCCA. We hypothesize that the anti-inflammatory properties of apremilast may play a role in the 
decreasing scalp inflammation in patients with CCCA and will prevent further hair loss and potentially 
induce hair regrowth in patients with mild to moderate disease. 
 
Background 
 
Central centrifugal cicatricial alopecia (CCCA) represents the most common type of scarring alopecia in 
women of African American descent (1,2). Clinically, hair loss starts at the vertex of the scalp and 
progresses circumferentially. Microscopically, in the early stage, it is characterized by an inflammatory, 
lymphocytic perifollicular infiltrate and perifollicular fibroplasia (3,4). 
 
The etiology of CCCA remains incompletely understood, but appears to be multifactorial. Hair-grooming 
practices involving heat, chemical processing, extensions and braids have largely been implicated, 
however with inconsistent supporting data (5-8). More recent literature highlights a possible metabolic 
dysregulation (8). A baseline pro-inflammatory state in afro-texture natural hair has been documented. 
Pro-inflammatory cytokine IL-1α was found to be 18 times higher in scalp sebum than anti-inflammatory 
cytokine IL-1R antagonist in a study of women with afro-texture natural hair (9). Genetics have also 
shown significance (8). 
 
The management of CCCA remains a challenge as there are no published treatment guidelines. Current 
therapies aim to decrease inflammation in order to prevent further hair loss. Common clinical practice 
includes encouraging modification of hair-grooming techniques in addition to the use of topical 
corticosteroids, topical immunomodulators (tacrolimus and pimecrolimus), intralesional corticosteroids, 
anti-inflammatory antibiotics (tetracycline and doxycycline) and antimalarials (hydroxychloroquine) 
(4,7,10). The use of cyclosporine, mycophenolate mofetil and hair transplantation have also been 
described in the literature (4). Treatment success has largely been reported in anecdotal reports, as there 
are no published case-controlled studies documenting effective treatment. 


 
Apremilast, an oral PDE4 inhibitor, has been shown to be effective in the treatment of moderate to severe 
plaque psoriasis and psoriatic arthropathy (11). In vitro studies have demonstrated anti-inflammatory 
properties, with inhibition of inflammatory mediators TNF, IFN, CXCL9, IL-2, IL-12, IL-23, macrophage 
inflammatory protein (MIP)-1a, monocyte chemoattractant protein (MCP)-1 and granulocyte 
macrophage-colony stimulating factor (GM-CSF) (12). CCCA is described as an inflammatory condition 
consistent with the characteristic lymphocytic infiltrate on histopathology in early stages (3,4). While the 
literature on inflammatory cytokines specific to CCCA is sparse, the anti-inflammatory properties of 
apremilast offer a possible therapeutic option for CCCA. 
 
Setting of the Human Research 
All research activity will take place at Mount Sinai Department of Dermatology. 
 
Resources Available to Conduct the Human Research 
 
The research team consists of the Principal Investigator, Sub-Investigator, and Research Coordinators. We 
do not foresee any difficulties in recruiting the suggested number of patients for this research study.  
 
All members of the study team have several years of research experience and have all completed the 
required trainings and certifications mandated by our IRB.  
 
All research team members have read and understand the protocol and all study related procedures. 
 
 
Study Design 
 
a) Recruitment Methods 
 
Subjects will be recruited from the dermatology faculty practices and the dermatology 
resident clinics in the Mount Sinai Health System. Once approved by the Sponsor, we will 
use IRB approved flyers, online advertisements (including social media postings and 
clinical trials listing services) as well as questionnaires and phone scripts. 
 
b) Inclusion and Exclusion Criteria 
Inclusion: 
1. Provide written, signed and dated informed consent prior to initiating any study-
related activities. 
2. Females of African ancestry >18 years of age at the time of screening 
3. Clinical diagnosis of mild to moderate vertex-predominant CCCA as defined by 
CHLG stages 1B, 2B, 3B  
4. Punch biopsy at screening, or punch biopsy of the scalp within six months prior to 
screening visit, consistent with CCCA.  


5. Females of childbearing potential (FCBP) must have a negative pregnancy test at 
Screening and Baseline.  While on investigational product and for at least 28 days 
after taking the last dose of investigational product, FCBP who engage in activity in 
which conception is possible must use one of the approved contraceptive options 
described below:  
Option 1:  Any one of the following highly effective methods:  hormonal 
contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine 
device (IUD); tubal ligation; or partner’s vasectomy; 
OR  
Option 2:  Male or female condom (latex condom or nonlatex condom NOT made 
out of natural [animal] membrane [for example, polyurethane]; PLUS one 
additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with 
spermicide; or (c) contraceptive sponge with spermicide. 
 
6. Must be in general good health as judged by the Investigator, based on medical history and 
physical examination. (NOTE: The definition of good health means a subject does not have 
uncontrolled significant co-morbid conditions).   
 
Exclusion: 
1. Systemic or intralesional treatment of CCCA for 4 weeks prior to baseline visit, 
including but not limited to corticosteroids (systemic, intralesional), oral tetracycline 
antibiotics, and oral anti-inflammatory medications 
2. Topical corticosteroid or calcineurin inhibitor treatment of CCCA for 2 weeks prior 
to baseline visit. 
3. Topical minoxidil for 4 weeks prior to baseline visit. 
4. Severe or end-stage CCCA with CHLG as defined as CHLG >3  
5. CCCA with frontal accentuation pattern as defined as CHLG 1A to 5A. 
6. Diagnosis of other dermatologic diagnosis or condition that, in the opinion of the 
investigator, would interfere with diagnosis, examination, or treatment of the studied 
condition (i.e. lichen planopilaris*, systemic lupus, cutaneous lupus) or would require 
treatment with systemic steroids, topical or intralesional steroids on the scalp, or 
systemic tetracycline antibiotic therapy during the duration of the study. 
*based on clinico-pathologic correlation 
7. Other than the disease under study, any clinically significant (as determined by the 
Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, 
hematologic, immunologic disease, or other major disease that is currently uncontrolled. 
8. Malignancy or history of malignancy, except for: 
 treated [ie, cured] basal cell or squamous cell in situ skin carcinomas;  
 treated [ie, cured] cervical intraepithelial neoplasia (CIN) or carcinoma in situ of 
cervix  with no evidence of recurrence within the previous 5 years. 


9. Any condition, including the presence of laboratory abnormalities, which would place the 
subject at unacceptable risk if he/she were to participate in the study. 
10. Use of systemic immunosuppressive drugs (including, but not limited to, cyclosporine, 
corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, or tacrolimus) within 
four weeks prior to Baseline/Randomization (Visit 2).  
11. Prior history of suicide attempt at any time in the subject’s life time prior to screening or 
randomization, or major psychiatric illness requiring hospitalization within the last 3 years. 
12. Pregnant or breast feeding.  
13. Subjects not willing to implement the following suggested hair care practices and/or 
maintain the same or similar hair style for the duration of study: 
 Shampoo hair every 7 days with a conditioning shampoo 
 Condition hair every 7 days with a deep or reconstructive conditioner 
 Towel-dry hair before exposing it to a dryer to minimize excessive heat 
 Comb hair daily with a wide-toothed comb; gently pass the comb through hair 
starting from the ends and working your way up to the roots 
 Avoid heavy pomades and hair oils to scalp; opt for silicone based products or 
light pomades to hair shafts 
 Limit use of styling gels 
 Limit traction-associated hair styles (e.g. tight braids, tight weaves, tight 
cornrows) as determined by investigator  
 Avoid chemical or thermal injury to scalp during hair styling process 
 Chemical relaxer treatments can be used as long as there is no associated scalp 
injury (i.e. tingling, burning, pain) 
 Maintain the same hair style throughout the study i.e. weave or braids present 
at baseline must be maintained through the end of the study; weaves or braids 
may be redone during the study if needed, but should resemble the subject’s 
hair style at baseline, if possible. 
14. Use of any investigational drug within 4 weeks prior to randomization, or 
5 pharmacokinetic/pharmacodynamics half-lives, if known (whichever is longer). 
15. Prior treatment with apremilast 
16. History of allergy to any component of the IP 
17. Active substance abuse or a history of substance abuse within 6 months prior to Screening. 
 
c) Number of Subjects 
Up to 40 patients with CCCA will be screened with a goal of 20 total subjects randomized. 
All 20 randomized subjects are expected to complete all study procedures. Individuals who 
provide informed consent and fail to meet all of the inclusion and exclusion criteria during 
the initial evaluation will be considered a “screening failure.” 


 
d) Study Timelines 
The study will consist of 8 to 10 visits over up to 30 weeks (4 week screening period, 24 
weeks enrolled in study, optional 2 week follow-up for suture removal). Study visits will 
be conducted at Screening (Visit 1), Baseline (Visit 2, Week 0), Week 4 (Visit 3), Week 8 
(Visit 4), Week 12 (Visit 5), Week 16 (Visit 6), Week 20 (Visit 7), Week 
24/Discontinuation (Visit 8). For subjects undergoing punch biopsy, additional suture 
removal visits (Visits 1a and 8a) may also occur 2 weeks after the baseline and week 
24/discontinuation visits.  
Enrollment will occur over a 12 month period from May 2018 to May 2019. 
 
e) Endpoints 
 
Primary Endpoint:  
 
1. Physician Global Assessment of Improvement (PGA-I) at week 24 
At baseline, week 12, and week 24, trained study personnel will take standardized photos of 
the scalp. These photographs will be provided to a panel of three dermatologists with 
expertise in CCCA, each of whom will review the photographs at baseline, week 12 and 
week 24. Investigators will assess the improvement in hair loss severity using PGA-I. PGA-I 
will range from -3 (significant worsening) to 3 (significant improvement). Treatment 
response will be considered no change (0) or improvement (+1 to +3) in CCCA. 
 
 
Secondary Endpoints: 
1. Change in CCCA Investigator Global Severity Score (IGSS) at week 24 compared to 
baseline 
 
Blinded investigators will review standardized photographs of the scalp and assess change in 
hair loss severity using a CCCA Investigator Global Severity Score (IGSS). Treatment 
response will be considered no change or improvement in IGSS. 
 
CCCA Investigator Global Severity Score (IGSS): 
0 (no hair loss), 1 (subtle features of CCCA, e.g. early loss of follicular ostia, <5% 
involvement of vertex scalp), 2 (mild features of CCCA, e.g. 5-10% involvement of vertex), 
3 (mild to moderate features of CCCA, e.g. 11-25% involvement of vertex), 4 (moderate 
features of CCCA, e.g. >25 and <50% involvement of vertex), 5 (moderate to severe CCCA 
e.g. 50-75% involvement of vertex), 6 (severe CCCA, e.g. >75% involvement of vertex) 
 
2.  Change in Central Hair Loss Grade (CHLG) at week 24 compared to baseline 
 
The change in central scalp alopecia will be determined using a standardized visual scale called 
Central Hair Loss Grade (CHLG) that has been found to be reliable in dermatologists 
experienced in hair disorders (13). The photographic scale grades pattern and severity of central 
hair loss in African American women, wherein hair loss is characterized by either frontal (A) or 
vertex (B) predominant. Degree of severity of hair loss is graded on a 6-point visual scale 


(pattern 0: no hair loss, pattern 1-2: mild hair loss, pattern 3-5: more severe hair loss). 
Treatment response will be considered no change or decrease (improvement) in CHLG. 
 
3.  Change in subject VAS of hair loss severity at weeks 12 and 24 compared to baseline 
 
The VAS is a numerical scale used to assess patients’ perception of hair loss severity. Subjects 
will be asked to complete the VAS scale at all scheduled visits. The evaluation is a 10cm long 
line on which the subjects indicate the severity of their condition from “0” (complete loss of 
hair in affected area – ie no visible hairs on central scalp) to “10” (full growth/regrowth in 
affected area—ie no visible hair loss on central scalp). Treatment response will be defined as 
no change or improvement in VAS. 
 
 
4.  Global Assessment of Improvement (PaGA-I) at 24 weeks 
At week 12 and week 24, subjects will be asked to assess the improvement in hair loss severity 
on a PaGA-I patient questionnaire. PaGA-I will range from -3 (significant worsening) to 3 
(significant improvement). Treatment response will be defined as no change (0) or 
improvement (+1 to +3) in CCCA. 
 
 
5.  Change in subject rating of symptom severity (pruritus, burning, pain) at weeks 12 and 
24 compared to baseline 
 
Subjects will complete a symptom severity questionnaire consisting of 3 numeric rating scales 
(NRS) measuring severity of pruritus, burning, and pain (14). The NRS will range from 0 (no 
symptoms) to 10 (severe symptoms). Patients indicate the intensity of each symptom (pruritus, 
burning, or pain) by choosing a number from 0 to 10 that corresponds to the severity of that 
symptom. Subjects will complete the 3 NRS’ at all scheduled visits.  
 
6. Change from baseline in Dermatology Life Quality Index (DLQI) total score at week 24 
Subjects will complete a DLQI at baseline, week 12, and week 24. Change in DLQI total score 
between baseline and week 24 will be assessed. 
 
 
b) Procedures Involved in the Human Research 
 
Table 1: Assessment Schedule 


1 Visit 1a will only be performed in subjects requiring a screening period of >2 weeks such that 
suture removal can occur within 2 weeks after punch biopsy. Visit 1a will be performed 2 weeks 
(+/- 3 days) after screening visit. 
2  Visit 8a will only be performed in subject who undergo a punch biopsy at visit 8 such that 
sutures can be removed. 
Visit 1 
1a1 
2 
3 
4 
5 
6 
7 
8 
8a2 
Week -4 to 
BL 
-2 to 
BL 
0 
(BL) 
4 
8 
12 
16 
20 
24 
ET/ 
EOT 
26 
Visit Window (days)  
±3 
 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
Assessment 
 
 
 
 
 
 
 
 
 
 
Informed Consent 
X 
 
 
 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
 
 
Inclusion/Exclusion 
X 
 
X 
 
 
 
 
 
 
 
Medical History 
X 
 
 
 
 
 
 
 
 
 
AE/SAE assessment 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hair care practice history 
X 
 
 
 
 
 
 
 
 
 
CCCA treatment history 
X 
 
 
 
 
 
 
 
 
 
Concomitant medications 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Vital Signs 
X 
 
X 
X 
X 
X 
X 
X 
X 
 
Height and Weight 
X 
 
X 
 
 
 
 
 
X 
 
Physical Examination 
X 
 
X 
 
 
X 
 
 
X 
 
Scalp Examination 
X 
 
X 
 
 
X 
 
 
X 
 
Photography 
X 
 
X 
X 
X 
X 
X 
X 
X 
 
Punch Biopsy 
X3 
 
 
 
 
 
 
 
X4 
 
Suture Removal 
 
X5 
X 
 
 
 
 
 
 
X 
Dermatoscopic examination of scalp 
X 
 
 
 
 
 
 
 
X 
 
Urine Pregnancy Test 
 
 
X 
X 
X 
X 
X 
X 
X 
 
Serum pregnancy test 
X 
 
 
 
 
 
 
 
 
 
Investigator CCCA Investigator 
Global Severity Score (IGSS) - 
Photograph 
 
 
X 
 
 
X 
 
 
X 
 
Physician Global Assessment of 
Improvement (PGA-I) – Photograph 
 
 
 
 
 
X 
 
 
X 
 
Investigator grading using CHLG  - 
In Person Exam 
X 
 
X 
 
 
X 
 
 
X 
 
Patient grading of pruritus, burning, 
pain severity, and overall CCCA 
severity 
 
 
X 
X 
X 
X 
X 
X 
X 
 
Patient Global Assessment of 
Improvement (PaGA-I) 
 
 
 
 
 
X 
 
 
X 
 
Dermatology Life Quality Index 
(DLQI) 
 
 
X 
 
 
X 
 
 
X 
 
Study Drug Training 
 
 
X 
 
 
 
 
 
 
 
Study Drug Dispensation and Return 
 
 
X 
X 
X 
X 
X 
X 
X 
 
Hair care diary distribution/collection 
 
 
X 
X 
X 
X 
X 
X 
X 
 


3 May be omitted in subjects who have undergone a punch biopsy confirming a diagnosis of CCCA 
within 6 months prior to the screening visit, at the discretion of the investigator.  
4 optional post-treatment biopsy 
 
5 Suture removal will either occur at visit 1a or 2 
 
Prior to the start of the study, potential subjects will be given an IRB-approved Informed Consent 
Document (ICD) containing a Health Insurance Portability and Accountability Act (HIPAA) 
disclosure agreement to read, understand, and sign. After providing informed consent, subjects 
will be assessed for study eligibility at the Screening visit (day -28 to day -1). The PI or a 
medically qualified designee must review this information (i.e. medical history, concomitant 
medication, and eligibility review) for each subject to confirm their eligibility before enrollment. 
 
A total of 20 subjects who meet eligibility criteria will undergo Baseline / Day 0 assessments. At 
this Baseline visit, subjects will receive the first oral dose of study drug (apremilast). All subjects 
will receive study drug training. Study drug will be dispensed at baseline and then every 4 weeks. 
Un-used drug will be returned to the site at each visit. 
 
Subjects will return for visits every four weeks through Week 24 (Weeks 4, 8, 12, 16, 20 and 24) 
so that a review of concomitant medications and adverse events can be assessed. The PI or 
designee will interview the subjects to collect and record any adverse events (AEs) or changes to 
health/concomitant medications that may have occurred since the previous visit. Additional 
procedures and assessments will be performed as outlined in table 1. 
 
If a subject terminates early or chooses to discontinue the study, he/she will be asked to return for 
a final visit, at which time the procedures for visit 24 will be performed. Whether optional punch 
biopsy will be offered and performed is at the discretion of the investigator.    
 
Apremilast will be provided as 10-, 20-, or 30-mg tablets. Apremilast will be taken orally twice 
daily, approximately 12 hours apart. Apremilast can be administered without regard to meals, and 
tablets should not be crushed, split, or chewed.  
 
When subjects first start to take apremilast, the dose will be titrated in 10-mg/day increments. 
Following the 5-day titration, the recommended maintenance dosage is 30 mg twice daily taken 
orally starting on Day 6. This titration is intended to reduce the gastrointestinal symptoms 
associated with initial therapy.  
 
Day 1: 10 mg in morning 
Day 2: 10 mg in morning and 10 mg in evening 
Day 3: 10 mg in morning and 20 mg in evening  
Day 4: 20 mg in morning and 20 mg in evening  
Day 5: 20 mg in morning and 30 mg in evening  
Day 6 and thereafter: 30 mg twice daily 
 
 
The procedures and assessment performed during this study are described in detail below: 
 


Informed Consent: Prior to the start of the study, potential subjects will be given an IRB-
approved Informed Consent Document (ICD) containing a Health Insurance Portability and 
Accountability Act (HIPAA) disclosure agreement to read, understand, and sign. All questions 
about the study should be answered to the satisfaction of the candidate subject. They will have all 
of their study-related questions answered by the PI or designee, and if they agree to participate, the 
subject will sign the ICF. The subjects will retain one original copy and one photocopy will be 
kept in the study file. The subjects who sign an ICF will be assigned a screening number. 
 
Demographics: Subjects will be asked to complete a questionnaire about their demographics at 
the screening visit. 
 
Eligibility Assessment (Inclusion/Exclusion): After providing informed consent, subjects will be 
assessed for study eligibility at the Screening visit (day -28 to day -1), which includes limited 
physical examination, scalp examination, vital signs, height and weight, investigator severity 
ratings, clinical photography, pre-treatment punch biopsy of an area affected by CCCA (if not 
performed within 6 months prior to screening visit), review of medical history and concomitant 
medications as well as prior medications/treatments, and serum pregnancy test (if applicable). 
These assessments will be described below. The PI or a medically qualified designee must review 
this information (i.e. medical history, concomitant medication, and eligibility review) for each 
subject to confirm their eligibility before enrollment. Eligibility will be assessed at Screening and 
Baseline visits. 
 
Medical History and Concomitant Medications: At the screening visit, subjects will be asked 
about current medical conditions or history of any medical conditions. Subjects will be asked 
about history of systemic or discoid lupus, lichen planus, other autoimmune disorders, severe 
acne, hidradenitis suppurativa, keloids, syphilis, sarcoidosis, alopecia areata, female pattern 
alopecia, frontal fibrosing alopecia, acne keloidalis nuchae, liver disease, and recurrent infections, 
in addition to other significant medical problems. Subjects will also be asked about current 
medication use and use of medications for 1 month prior to screening. Concomitant medications 
will be reviewed and recorded at every scheduled visit. 
 
Hair Care Practice History and CCCA Treatment History: At the screening visit, subjects will 
be asked about their current or past hair care practices and use of treatments for CCCA based on 
the NAHRS workshop guidelines (15).  
 
Vital Signs: Vital signs will be assessed at all scheduled study visits. Whether action needs to be 
taken regarding abnormal vital signs (as defined below) will be at the investigator’s discretion. 
After the subject has been sitting for at least five minutes with back supported and both feet on the 
ground, systolic and diastolic blood pressure (BP) will be measured using an appropriately sized 
cuff. Pulse will also be measured using either an automated machine or manually. Normal Blood 
pressure will be defined as systolic 90 to <120mmHg and diastolic 60 to <80mm Hg. Notable 
blood pressure will be hypertension (systolic ≥140 mmHg and/or diastolic ≥100 mmHg). A 
normal pulse rate will be defined as 60 to 100 beats per minute. Notable pulse rates will be defined 
as bradycardia (<50bpm) and tachycardia (>100bpm).  
 
Height and Weight: Height and weight will be measured by a designated site individual at 
screening, baseline, and week 24 visits. 
 


Physical examination: Physical examination will be performed by the investigator, sub-
investigator, or other qualified individuals at screening, baseline, week 12, and week 24. This will 
include examination of the heart, lungs, abdomen, extremities, and skin, as well as any additional 
body systems as deemed necessary by the investigator.  
 
Scalp Examination: A scalp examination will be performed based on the NAHRS workshop 
physical examination checklist (15) at screening, baseline, week 12, and week 24. The scalp 
examination will include the following parameters: 
 Extent of hair loss (graded from 0- none to 3 - severe) 
o Percent of scalp surface involved 
o Smallest dimension 
o Largest dimension 
o Most representative dimension 
 Erythema, scale/crusting, pustules, absence follicular markings, anagen/total pulls (pull 
test), perifollicular hyperkeratosis, telangiectasia, atrophy, pigmentary changes, keratosis 
pilaris graded from 0- none to 3-severe. 
 Number of follicular openings and hair count within a 1cm2 representative region of 
CCCA (at the active border of the lesion on scalp). The exact location will be recorded 
using distance from the screening visit punch biopsy site.  
 
Photography: Standardized photographs will be taken of the frontal and central scalp. The 
photograph will be taken such that the entire vertex of the scalp is included in the picture, at a 
distance of 3 feet. Photographs will be taken at all scheduled visits.   
 
Punch biopsy: A 4mm punch biopsy of the scalp into and including the subcutaneous tissue will 
be performed at the screening visit for diagnosis of CCCA. The biopsy will be performed at the 
active border of the lesional scalp after dermatoscopic examination; if there are multiple distinct 
area of alopecia, dermoscopy and biopsy will be performed at the largest area (greatest diameter) 
affected by CCCA. If peripilar white/gray halos are identified on dermoscopy, an area that 
demonstrates peripilar white/gray halo(s) will be chosen, as this dermatoscopic finding is 
associated with 100% specificity and 94.12% sensitivity for CCCA (16,17). The site of biopsy will 
be marked with a marker and a photograph will be taken to record the location. In addition, the site 
of the biopsy will be recorded using distance from bilateral top of the pinna. This biopsy specimen 
will also be used as a comparison for the optional post-treatment biopsy. If performed, the post-
treatment biopsy will be obtained at the same site as the original biopsy, as identified via picture 
and distance from anatomic landmarks. 
The biopsy specimens will be evaluated based on the NAHRS Pathology Evaluation for Cicatricial 
Alopecia flowsheet. The post-treatment biopsy will be evaluated for changes in inflammation 
compared to the pre-treatment biopsy. Changes in hair follicle structure and density (vellus and 
terminal), adnexal structures, epithelium, fibrous tissue, and interstitial will also be evaluated. 
 
If a punch biopsy of the affected area of the scalp was performed within 6 months of the screening 
visit, this may replace the pre-treatment punch biopsy. In this case, the initial biopsy report will be 
obtained to confirm a diagnosis of CCCA by clinicopathologic correlation. In addition, unstained 
slides and biopsy block may be obtained from the initial pathology lab, if available, for evaluation 
by the pathologist in this study. The biopsy specimen will be evaluated based on the NAHRS 
Pathology Evaluation for Cicatricial Alopecia flowsheet. If the unstained slides or biopsy block 
cannot be obtained, or the obtained specimen is insufficient for analysis using the NAHRs 


flowsheet, a new punch biopsy may be performed at the screening visit as deemed necessary by 
the investigator. 
 
Dermatoscopic evaluation of the scalp: Dermoscopy will be used to assist in determining the 
anatomic location of the scalp biopsy as described above. 
 
Suture Removal: In those who have undergone punch biopsy at screening, sutures will be 
removed at visit 1a (for those requiring a screening period of >2 weeks) or visit 2 (for those 
requiring a screening period of ≤ 2 weeks). Suture removal may occur as early as 1 week after 
screening and as late as 2 weeks (+ 3 day window) after screening. For those who undergo 
optional punch biopsy at the end of study visit (visit 8), sutures will be removed 2 weeks later (+/- 
3 day window) at visit 8a. Visit 8a will only be performed in subjects requiring suture removal and 
will not be performed in subjects who forego the end of study biopsy. 
 
Investigator CCCA Investigator Global Severity Score (IGSS): Standardized photographs will 
be provided to a panel of three dermatologists with expertise in CCCA, each of whom will review 
the photographs at baseline, week 12 and week 24. Blinded investigators will assess change in hair 
loss severity using a global severity scale.  The same blinded investigators will evaluate the 
baseline and week 24 photographs. 
CCCA Investigator Global Severity Score: 
 0 (no hair loss) 
 1 (subtle features of CCCA, e.g. early loss of follicular ostia, <5% involvement of vertex 
scalp) 
 2 (mild features of CCCA, e.g. 5-10% involvement of vertex) 
 3 (mild to moderate features of CCCA, e.g. 11-25% involvement of vertex) 
 4 (moderate features of CCCA, e.g. >25 and <50% involvement of vertex) 
 5 (moderate to severe CCCA e.g. 50-75% involvement of vertex) 
 6 (severe CCCA, e.g. >75% involvement of vertex) 
 
Investigator Determination of CHLG: The change in central scalp alopecia will be determined 
using a standardized visual scale called Central Hair Loss Grade (CHLG) that has been found to 
be reliable in dermatologists experienced in hair disorders (13). The photographic scale grades 
pattern and severity of central hair loss in African American women, wherein hair loss is 
characterized by either frontal (A) or vertex (B) predominant. Degree of severity of hair loss is 
graded on a 6-point visual scale (pattern 0: no hair loss, pattern 1-2: mild hair loss, pattern 3-5: 
more severe hair loss). CHLG will be determined at screening, baseline, week 12 and week 24.  
 
Investigator Global Assessment of Improvement (PGA-I): A panel of three blinded 
investigator will be provided with photographs at baseline, week 12, and week 24. The 
investigator will determine the PGA-I at weeks 12 and 24 compared to baseline, which will allow 
the investigator to rate improvement or worsening in the overall clinical condition. The scale will 
range from -3 (significantly worse) to 3 (significantly improved), with 0 being no change. 
 
Subject VAS of hair loss severity: The VAS is a numerical scale used to assess patients’ 
perception of hair loss severity. Subjects will be asked to complete the VAS scale at all scheduled 
visits. The evaluation is scored from 0 (complete loss of hair in affected area – i.e. no visible hairs 
on central scalp) to 10 (full growth/regrowth in affected area—i.e. no visible hair loss on central 
scalp).  


 
Patient Global Assessment of Improvement (PaGA-I): Patient will complete a PaGA-I 
questionnaire at weeks 12 and 24 to ask about improvement or worsening in their overall clinical 
condition. The scale will range from -3 (significantly worse) to 3 (significantly improved), with 0 
being no change. 
 
Subject grading of symptom severity (pruritus, burning, and pain severity): Subjects will 
complete a questionnaire containing 3 distinct numeric rating scales (NRS). Patients with 
indicated the intensity of (1) pruritus, (2) burning, and (3) pain by choosing a number from 0 to 10 
that corresponds to their symptoms. A number 0 refers to no symptoms (pruritus/burning/pain) 
and a 10 refers to the most severe symptoms (14). Subjects will complete the NRS of symptom 
severity at all scheduled visits.  
 
Dermatology Life Quality Index (DLQI): DLQI is a validated 10-question questionnaire 
developed to address quality of life in patients with dermatological disorders. It has previously 
been used with success to assess the impact of scarring and non-scarring alopecia on quality of life 
(18,19). Patients will be asked to fill out a DLQI at baseline, week 12, and week 24. 
 
Hair Care Diary: Subjects will be provided with a diary for the duration of the study during 
which they will be asked to record hair care practices (use of shampoo, conditioner, straightening, 
weaves, braids, etc.). They will also record symptoms of the scalp, including itching, burning, and 
pain. Additional medications taken and adverse events will be recorded. 
 
Urine and Serum Pregnancy tests:  Venipuncture will be performed at screening visit in order to 
perform serum pregnancy test as required by local IRB. Urine pregnancy test will be performed at 
all subsequent study visits for women of child-bearing potential. A woman is considered post-
menopausal if she has not had a menstrual period in >12 months. 
 
Adverse Events and Serious Adverse Events: An adverse event (AE) is any noxious, 
unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a 
subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant 
illness, an injury, or any concomitant impairment of the subject’s health, including laboratory test 
values (as specified by the criteria below), regardless of etiology. Any medical condition that was 
present prior to study treatment and that remains unchanged or improved should not be recorded 
as an AE. If there is a worsening of that medical condition this should be considered an AE. A 
diagnosis or syndrome should be recorded on the AE page of the Case Report Form rather than the 
individual signs or symptoms of the diagnosis or syndrome.   
 
All AEs will be recorded by the Investigator(s) from the time of signing the informed consent 
through the end of the designated follow-up period. 
 
 
 
Serious adverse event: A serious adverse event (SAE) is any AE which: 
 Results in death 
 Is life-threatening (i.e., in the opinion of the Investigator(s) the subject is at 
immediate risk of death from the AE) 


 Requires inpatient hospitalization or prolongation of existing hospitalization 
 Results in persistent or significant disability/incapacity (a substantial disruption 
of the subject’s ability to conduct normal life functions) 
 Is a congenital anomaly/birth defect 
 Constitutes an important medical event 
Important medical events are defined as those occurrences that may not be immediately life 
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious. 
Events not considered to be SAEs are hospitalizations which: were planned before entry into the 
clinical study; are for elective treatment of a condition unrelated to the studied indication or its 
treatment; occur on an emergency outpatient basis and do not result in admission (unless fulfilling 
other criteria above); are part of the normal treatment or monitoring of the studied indication and 
are not associated with any deterioration in condition. 
If an AE is considered serious, both the AE pages of the CRF and the SAE Report Form must be 
completed. 
For each SAE, the Investigator(s) will provide information on severity, start and stop dates, 
relationship to study drug, action taken regarding study drug, and outcome. 
Classification of severity 
For both AEs and SAEs, the investigator(s) must assess the severity of the event. The AEs will be 
evaluated for severity according to the following scale: 
Grade 1 = Mild 
Grade 2 = Moderate 
Grade 3 = Severe 
Classification of Relationship/Causality of adverse events (SAE/AE) to study drug 
The Investigator(s) must determine the relationship between the administration of study drug and 
the occurrence of an AE/SAE as Not Suspected or Suspected as defined below: 
Not suspected: 
The temporal relationship of the adverse event to study 
drug administration makes a causal relationship 
unlikely or remote, or other medications, therapeutic 
interventions, or underlying conditions provide a 
sufficient explanation for the observed event 
Suspected: 
The temporal relationship of the adverse event to study 
drug administration makes a causal relationship 
possible, and other medications, therapeutic 
interventions, or underlying conditions do not provide a 
sufficient explanation for the observed event. 
 


Immediate reporting of serious adverse events 
Any AE that meets the any criterion for a SAE requires the completion of an SAE Report 
Form in addition to being recorded on the AE pages of the CRF.  The Investigator(s) is 
required to ensure that the data on these forms is accurate and consistent.  This applies to all 
SAEs, regardless of relationship to study drug, that occur during the study, those made known 
to the Investigator(s) within 30 days after a subject’s last dose of study drug, and those made 
known to the investigator(s) at anytime that are suspected of being related to study drug. 
The SAE must be reported immediately (i.e., within 24 hours of the Investigators’ knowledge 
of the event) to Amgen Safety by facsimile.  A written report (prepared by the Investigator(s) 
using an SAE Report Form or a 3500A Medwatch form  is to be faxed to Safety (see below for 
contact information). 
Amgen Drug Safety Contact Information: 
Fax:                 888-814-8653 
 
The SAE report should provide a detailed description of the SAE.  If a subject has died and an 
autopsy has been performed, copies of the autopsy report and death certificate are to be sent to 
Amgen as soon as these become available.  Any follow-up data will be detailed in a 
subsequent SAE Report Form or Medwatch form and sent to Amgen. 
The Investigator(s) is responsible for informing the Institutional Review Board/Ethics 
Committee (IRB/IEC) of the SAE and providing them with all relevant initial and follow-up 
information about the event. The Investigator(s) must keep copies of all SAE information, 
including correspondence with Celgene and the IRB/IEC, on file.  All SAEs that have not 
resolved upon discontinuation of the subject’s participation in the study must be followed until 
either the event resolves completely, stabilizes/resolves with sequelae, or returns to baseline (if 
a baseline value is available). 
Pregnancy: Pregnancies and suspected pregnancies (including a positive pregnancy test 
regardless of age or disease state) of a female subject or the female partner of a male subject 
occurring while the subject is on study drug, or within 30 days of the subject’s last dose of 
study drug, are considered immediately reportable events.  Study drug is to be discontinued 
immediately and the subject instructed to return any unused portion of the study drug to the 
investigator(s).  The pregnancy, suspected pregnancy, or positive pregnancy test must be 
reported to Amgen Safety immediately facsimile using the Pregnancy Report form provided by 
Amgen. 
The female should be referred to an obstetrician-gynecologist experienced in reproductive 
toxicity for further evaluation and counseling. 
The Investigator(s) will follow the female subject until completion of the pregnancy, and must 
notify Amgen Safety of the outcome of the pregnancy as a follow-up on the follow up 
Pregnancy Reporting form. 
If the outcome of the pregnancy meets the criteria for immediate classification as a SAE (i.e., 
spontaneous or therapeutic abortion [any congenital anomaly detected in an aborted fetus is to 
be documented], stillbirth, neonatal death, or congenital anomaly [including that in an aborted 
fetus]), the Investigator(s) should follow the procedures for reporting SAEs (i.e., report the 


event to Amgen Safety by facsimile within 24 hours of the Investigator’s knowledge of the 
event). 
In the case of a live “normal” birth, Amgen Safety should be advised by facsimile within 24 
hours of the Investigator’s knowledge of the event. 
All neonatal deaths that occur within 30 days of birth should be reported, without regard to 
causality, as SAEs.  In addition, any infant death after 30 days that the Investigator(s) suspects 
is related to the in utero exposure to the study drug should also be reported to Amgen Safety 
by facsimile within 24 hours of the Investigators’ knowledge of the event. 
If the female is found not to be pregnant, any determination regarding the subject’s continued 
participation in the study will be determined by the Investigator. 
 
Overdose: Abuse, withdrawal, sensitivity, or toxicity to an investigational product should be 
reported as an AE. Overdose, accidental or intentional, whether or not it is associated with an 
AE should be reported as an AE.  Any sequela of an accidental or intentional overdose of an 
investigational product should be reported as an AE. 
 
If the sequela of an overdose is an SAE, then the sequela must be reported on an SAE report 
form. The overdose resulting in the SAE should be identified as the cause of the event on the 
SAE report form but should not be reported as an SAE itself. 
 
In the event of an overdose, the subject should be monitored as appropriate and should receive 
supportive measures as necessary. There is no known specific antidote for apremilast 
overdose. 
Actual treatment should depend on the severity of the clinical situation and the judgment and 
experience of the treating physician. 
 
Overdose for this protocol, on a per dose basis, is defined as ingestion of any more than the 
amount prescribed of apremilast tablets in any 24 hour period whether by accident or 
intentionally.  
 
 
c) Specimen Banking 
The skin biopsy specimens (Screening and optional biopsy at Week 24) will be sent to, 
processed, and stored at the designated pathology facility according to standard operating 
procedures. The specimens will be identified with subject ID number and time of biopsy.  
Since this study is designed to gain basic knowledge rather than to yield information directly 
related to patient care, the results are not entered in the participants’ medical records. If, at a later 
date, correlations of in-vitro tests and the patients’ clinical situation suggest that the results do bear 
on the patients’ health, an amended protocol will be submitted to the IRB so that results can be 
made available to the medical record. As all tissue is obtained for research purposes and not for 
routine clinical tests, the above outlined skin samples may be stored until used. Skin cells will be 
studied and de-identified samples may be shared with collaborating investigators at Mount Sinai in 
the future for further histology and immunochemistry. The samples will be stored indefinitely and 
will primarily be used for the scope of this study.  
 


Subjects will have the option to request destruction of their samples at any time, unless the 
samples have already been destroyed by the study team, and will not be used for any future 
studies. Samples will be stored at Mount Sinai indefinitely. Stored samples will be linked back to 
subjects via an ID#. Only clinical staff will have the link. Pathology personnel will not have 
access to the link, and will not have any identifiable information. 
 
d) Data Management and Confidentiality 
 
As used in this protocol, the term case report form (CRF) should be understood to refer to either a 
paper form or an electronic data record or both, depending on the data collection method used in 
this trial. All subject source documents are the site’s subject records and are to be maintained at 
the study site. These source documents must be attributable, legible, contemporaneous, original, 
and accurate.  
 
A CRF/source document is required and should be completed for each included subject. It is the 
PI's responsibility to ensure completion and to review and approve all CRFs/source documents. 
These must be signed by the PI or by an authorized staff member. These signatures serve to attest 
that the information contained on the CRFs/source documents is true. At all times, the PI has final 
personal responsibility for the accuracy and authenticity of all clinical and laboratory data entered 
on the CRFs/source documents.  SAE forms and pregnancy notification forms will be provided by 
the Sponsor.  
 
Good documentation practices should be used on all study documentation. The clinical study will 
be performed in accordance with the protocol, applicable standard operating procedures (SOPs), 
the International Conference on Harmonization Good Clinical Practice (ICH GCP) guidelines, and 
applicable local regulatory requirements and laws. 
 
The Sponsor requires that all records (e.g., ICFs, pathology reports, source documents, test article 
dispensing record, etc.) which support CRFs/source documentation of this study must be retained 
in the files of the responsible investigator for a period of 2 years from the time the final report is 
issued. 
If the investigator relocates, retires, or for any reason withdraws from the trial, the Sponsor should 
be prospectively notified. The study records must be transferred to an acceptable designee, such as 
another investigator, another institution, or to the Sponsor.  The investigator must obtain Sponsor's 
written permission before disposing of any records, even if retention requirements have been met.  
The Sponsor must be notified in writing of the name and address of the new custodian prior to re-
assignment/transfer. 
All records identifying the subject will be kept confidential and, to the extent permitted by 
the applicable laws and/or regulations, will not be made publicly available. Only the 
subject number will be recorded in the CRF. The code that links the subject to the subject’s 
ID# is stored on paper in a locked cabinet, accessible only by Department of Dermatology 
research personnel. Photographs will be stored on the camera for approximately one week 
before being transferred to the computer database. Study findings stored on a password- 
protected computer will be encrypted and stored in accordance with local data protection 
laws. As part of the informed consent process, the subjects will be informed in writing that 
representatives of the IRB, or regulatory authorities may inspect their medical records to 


verify the information collected, and that all personal information made available for 
inspection will be handled in strictest confidence and in accordance with local data 
protection laws. If the results of the study are published, the subject’s identity will remain 
confidential. Only the investigator will maintain a list to enable subjects to be identified. 
The data will be stored indefinitely.  
 
e) Provisions to Monitor the Data to Ensure the Safety of Subjects 
 
Part I: Elements of a Data and Safety Monitoring Plan 
 
MSSM Principal Monitor: 
Indicate whether this person is the PI, a Team Member, or is Independent: 
Last Name: Khattri (PI) 
First Name: Saakshi 
Academic Title: MD. 
Department: Dermatology 
Mailing Address: 
 
 
 
Phone: 212-523-3812 
Fax: 212-523-6293 
E-mail: Saakshi.khattri@mountsinai.org 
 
MSSM Additional Monitor: 
Indicate whether this person is the PI, a Team Member, or is Independent: 
Last Name: Sanabria-Gonzalez (Team Member) 
First Name: Ingrid 
Academic Title: Research Manager 
Department: Dermatology 
Mailing Address: 
 
 
 
Phone: 212-523-3812 
Fax: 212-523-6293 
E-mail: Ingrid.sanabria@mountsinai.org 
 
 
3. The principal monitor is the Principal Investigator. Please refer to curriculum vitae for further 
information. 
4.  The specific items that will be monitored for safety are adverse events, subject compliance with 
the protocol and withdrawals. Subjects will be monitored for adverse events the day of their 
participation in the study. Should subjects experience any adverse effects after their 
participation in the study, they will be instructed to contact the investigator(s) and make an 
appointment immediately.  
5. Accumulated safety data will be reviewed annually. 
6. N/A  
7. N/A 
8.  Adverse events will be graded using the Common Terminology Criteria for Adverse Events 
(CTCAE).    
9.   All data captured in this project will be reviewed for accuracy by the principal monitor and the 
additional monitor.  


10. Should a temporary or permanent suspension of our study occur, the occurrence will be     
      reported to the PPHS, sponsor, and IRB. 
 
  
Part II. Data Monitoring Committee/Data Safety Monitoring Board (DMC/DSMB) 
 
 
Not applicable 
 
f) Withdrawal of Subjects 
When an individual who has signed the ICF is not enrolled in the study or withdraws/is withdrawn 
prior to completing the study, the reason is to be documented on the Discontinuation/Completion 
Form (or equivalent) and in the final study report.  Reasons for subject withdrawal may include:  
 Not enrolled (e.g. fails to meet inclusion/exclusion criteria, chooses not to enroll, etc.) 
 Participant is determined to be ineligible after enrollment 
 Subject’s choice to withdraw 
 Investigator terminated (e.g. noncompliance, etc.) 
 Adverse Event 
 Lost to follow-up 
 Other 
 
Subjects may withdraw from the trial at any time at their request, or they may be withdrawn at any 
time at the discretion of the Sponsor, PI, or designee for safety, behavioral, or administrative 
reasons. Subjects may be withdrawn from this study without their consent if the research study is 
being stopped; or if the instructions of the study team have not been followed. 
 If a subject does not return for a scheduled visit, three documented attempts will be made to 
contact the subject in order to establish the reason for withdrawal, and the outcome will be 
documented.  The PI or designee should inquire about the reason for withdrawal, request that the 
subject return for a final visit, if applicable, and follow-up with the subject regarding any 
unresolved adverse events.   
 
Should a subject withdraw from the trial and also withdraw consent for disclosure of future 
information, no further evaluations should be performed and no additional data should be 
collected.  The PI and staff may retain and continue to use any data collected before such 
withdrawal of consent.  Removed or withdrawn subjects will not be replaced. 
 
If a subject fails to report to the test facility for a scheduled visit and cannot be rescheduled within 
the permitted window of time (as applicable), the Site should consult with the Sponsor to 
determine if the subject should be documented as having withdrawn/dropped from the study. 
 
 
Risks to Subjects 
 
Risks of Apremilast: 
 
As of 30 Nov 2016, apremilast has been given to more than 6700 subjects (people) in studies 
conducted by Celgene/Amgen. The following are the most commonly seen risks, discomforts and side 
effects in subjects who have taken apremilast: headache including tension headache, stuffiness 


or infections of the nose and throat (upper respiratory tract infections including nasopharyngitis), 
stomach upset (nausea), vomiting and diarrhea. Most of these side effects were mild to moderate 
in intensity and resolved with continued treatment. Similar side effects have been observed in 
studies that are running now. About 8 out of every 100 subjects treated have discontinued the 
study drug because of side effects. 
 
The following list of side effects is the ones that may be associated with the use of apremilast: 
 Very common: Diarrhea, Nausea (stomach upset), Vomiting 
 Common: Upper abdominal (stomach) pain, Indigestion, Frequent bowel movement, 
Heartburn, Fatigue, Bronchitis (infection of the tubes to the lungs), Redness/swelling/pain in 
the sinuses, Inflammation or infections of the nose and throat, Weight loss, Decreased appetite, 
Back pain, Headache (including tension and migraine), Difficulty sleeping, Depression, 
Cough, Rash, Dizziness, Weakness, Flu, Muscle pain, Numbness, Itchiness 
 Uncommon: Allergic reaction. 
 
Reports of various types of cancers, heart problems, and serious infections have been found from 
apremilast studies. However, these events in patients being treated with apremilast happened as often as 
those being treated with placebo (sugar pill). Drugs in the same family as apremilast have been shown to 
produce inflammation around the vessels of the skin (vasculitis) in rats and mice. Skin vasculitis has been 
rarely reported equally in patients taking apremilast or placebo.   
Depression and weight loss have been reported with the use of apremilast, thus, subjects will be 
questioned about any mood changes and weight loss at each visit.  
 
Blood Draws: 
Possible risks from needle puncture include fainting, pain, bruising, discomfort, tingling, bleeding, 
redness or formation of blood clots at the needle puncture site. In rare cases infections can occur. 
Biopsy Collection: 
Possible risks from a biopsy include the following: bleeding from the biopsy site, pain, local 
reaction to the anesthetic (lidocaine), infection or healing problems such as the possibility of a scar 
at the site. 
 
 
Provisions for Research Related Harm/Injury 
 
If a subject experiences a research injury, Mount Sinai West will provide or arrange for medical treatment 
at no cost. If the subject chooses to see their own personal doctor we will not offer to pay for the 
expenses. A research injury is any physical injury or illness caused by participation in the study. If a 
subject is injured by a medical treatment or procedure that would have been received even if the subject 
weren't in the study; that is not a research injury.  Payment for things such as lost wages, expenses other 
than medical care, or pain and suffering is not offered. To help avoid injury, it is very important to follow 
all study directions. 
 
Please be aware that some insurance plans may not pay for research-related injuries.  Subjects should 
contact their insurance company for more information. 
 


Unreimbursed medical expenses not covered by insurance or other third party coverage will be 
reimbursed by the sponsor for medical treatment for any injury that, in the opinion of the study doctor and 
the sponsor, is directly caused by the study drug/investigational product or by procedures required by the 
study protocol which would not have been performed as part of regular medical care. 
 
 
Provisions to Protect the Privacy Interests of Subjects 
 
Only subjects who have given us permission to contact them for studies will be contacted. All 
conversations with subjects and potential subjects will be conducted in a private examination room 
with the subject. Subjects’ privacy will be protected by performing any study-related procedures in 
a private examination room. Family members will be allowed to remain in the room only if the 
subject allows this. No information regarding the subject’s disease, treatment or the fact that 
he/she is involved in a study will be conveyed. Subjects will be made to feel at ease, by allowing 
them sufficient time to discuss the study and any potential queries. 
All parties will ensure protection of subject personal data and will not include subject names on any Sponsor 
forms, reports, publications, or in any other disclosures. In case of data transfer, Sponsor will maintain high 
standards of confidentiality and protection of subject personal data.   
The ICF (containing the HIPAA disclosure agreement) must be agreed to by Sponsor and the IRB and be 
in compliance and consistent with ICH GCP, local regulatory requirements, and legal requirements. 
The investigator must ensure that each study subject is fully informed about the nature and objectives of 
the trial, possible risks associated with participation. The investigator, or a trained person designated by the 
investigator, will obtain written informed consent on two copies from each subject before any trial-specific 
activity is performed.  The subject will retain one copy, and one will be kept in the study file. The ICF used 
in this trial, and any changes made during the course of the trial, must be prospectively approved by both 
the IRB and Sponsor before use.  
Economic Impact on Subjects 
Amgen, the manufacturer of the study drug will provide the study drug. Amgen also provided a grant 
toward study-related tests and procedures. While in the study, the subject will still need to get regular 
medical care. The subject will still have to pay for the costs of regular medical care that is not a part of 
this study. 
 
Taking part in this research study may lead to added costs to the subject. If the laboratory tests or physical 
examinations reveal information about his/her health, additional tests, treatments and doctors 
appointments may be required which could present additional costs to him/her or his/her insurance 
company. 
 
 
Payments to Subjects 
Subjects will be compensated $25.00 per completed visit, with the exception of the screening visit, 
for a total of $175.00 upon completion of the study. Subjects who complete only the screening 
visit will not be eligible for compensation.  
If the subject withdraws or is withdrawn before completing the study, he/she will receive an 
amount of money for the visits which have been completed.  They will not have to submit receipts 


to receive this reimbursement. This payment will come in the form of a check at the end of the 
subject’s participation in the study.  
 
Consent Process 
We will be obtaining written consent as a part of this study. No subject will be evaluated without a signed 
Informed Consent Form (ICF). The consent process will take place in a private exam room where the 
subject will have ample time to review and read the consent form.  
 
Subjects will be given time to ask questions and may take additional time to consider their options.  
 
Subjects will be informed that they do not have to participate and may withdraw consent at any time.  
 
After understanding and agreeing, the subject will express their consent to participate in the study by 
signing one original copy of the ICF. They will receive a copy of their signed document for their records. 
 
We will follow the SOP HRP-090 Informed Consent Process for Research. 
 
Process to Document Consent in Writing 
We will be using the standard IRB Informed Consent template. The ICF must be agreed to by the 
Sponsor and the IRB and must be in compliance with ICH GCP, local regulatory requirements, 
and legal requirements.  
The consent process and date that the consent is signed is documented in our source notes.  
Study personnel will adhere to “SOP HRP-091 Written Documentation of Consent”. 
 
Vulnerable Populations 
 
This project will not include any vulnerable population subjects. 
 
Multi-Site Human Research (Coordinating Center) 
This is single site project. 
 
Community-Based Participatory Research 
 
This project will not involve any community-based participation. 
 
 
Sharing of Results with Subjects 
 
At the completion of the study, subjects will have the right to access their protected health information that 
is created during this research study that relates to their treatment or to payment, provided such information 
is not exempted under certain laws and regulations.  To request this information, subjects should contact 
the study doctor at the address listed above. 
 


Subject to certain exceptions prescribed by law, subjects have a right to request access to the health 
information that we hold about and to request changes if the health information is incorrect or incomplete. 
Any request for access or corrections should be made to the principal doctor conducting this study. 
 
Once all data and results are finalized, a summary will be made available to subjects. 
 
External IRB Review History 
This project is not using an external IRB. 
 
Control of Drugs, Biologics, or Devices 
 
Study drug is stored in a combination-locked room accessible only by clinical trials personnel. All study 
materials should be stored at room temperature (59°-77°F), and the Site is responsible for maintaining 
temperature logs. All study products received and dispensed will be inventoried and accounted for 
throughout the study. The investigator must maintain adequate records documenting the receipt, use, loss, 
or other disposition of the products on the Product Accountability Log. The log must identify the 
investigational product and account for its disposition by subject, including specific dates and quantities 
dispensed and returned. The log must be signed by the individual who dispensed/retrieved the study product 
and copies must be provided to the sponsor for inclusion in the Trial Master File. 
 
At the completion of the study, all units of product dispensed (whether empty or containing unused product) 
must be collected by the Site and returned, along with un-dispensed product, to the Sponsor.  Any container 
not returned by the Site must be accounted for in writing.    
 
 
 
References: 
 
1. Whiting DA, Olsen EA. Central centrifugal cicatricial alopecia. Dermatol Ther. 2008;21(4):268–
278. 
2. Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a 
comparative practice survey. Cutis. 2007;80(5):387–394. 
3. Stefanato CM. Histopathology of alopecia: a clinicopathological approach to diagnosis. 
Histopathology. 2010;56: 24–38.  
4. Ogunleye TA, McMichael A, Olsen EA. Central centrifugal cicatricial alopecia: what has been 
achieved, current clues for future research. Dermatol Clin. 2014;32(2):173-81. doi: 
10.1016/j.det.2013.12.005. Epub 2014 Jan 22. 
5. Nnoruka EN. Hair loss: is there a relationship with hair care practices in Nigeria? Int J 
Dermatol.2005;44(suppl 1):13–7. 
6. Khumalo NP, Jessop S, Gumedze F, Ehrlich R. Hairdressing and the prevalence of scalp disease in 
African adults. Br J Dermatol. 2007;157(5):981–988. 
7. Suchonwanit P, Hector CE, Bin Saif GA, and McMichael AJ. Factors affecting the severity of 
central centrifugal cicatricial alopecia. Int J Dermatol. 2016;55: e338–e343.  
8. Kyei A, Bergfeld WF, Piliang M, et al. Medical and environmental risk factors for the 
development of central centrifugal cicatricial alopecia: a population study. Arch Dermatol. 
2011;147: 909–914. 
9. Beach A, Wilkinson KA, Gumedze Fet al. Baseline sebum IL-1α is higher than expected in afro-
textured hair: a risk factor for hair loss? J Cosmet Dermatol. 2012;11 (1):9–16. 


10. Olsen EA, Callender V, McMichael A, et al. Central hair loss in African American women: 
incidence and potential risk factors. J Am Acad Dermatol. 2011;64(2): 245–252. 
11. Keating GM.. Apremilast: A Review in Psoriasis and Psoriatic Arthritis. Drugs. 2017;77(4):459-
472. 
12. Schafer PH, Chen P, Fang L, Wang A, Chopra R. The pharmacodynamic impact of apremilast, an 
oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients 
with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial 
(PALACE 1). J Immunol Res. 2015;2015:906349. doi: 10.1155/2015/906349.  
13. Olsen EA, Callender V, Sperling L, et al. Central scalp alopecia photographic scale in African 
American women. Dermatol Ther. 2008;21:264–267. 
14. Saif GAB, McMichael A, Kwatra SG, Chan Y-H, Yosipovitch G. Central centrifugal cicatricial 
alopecia severity is associated with cowhage-induced itch. The British journal of dermatology. 
2013;168(2):253-256. doi:10.1111/bjd.12043. 
15. Olsen EA, Bergfeld WF, Cotsarelis G, et al. Summary 
of North American Hair Research Society (NAHRS)-sponsored Workshop on Cicatricial 
Alopecia, Duke University Medical Center, February 10 and 11, 2001. J Am Acad Dermatol. 
2003;48(1):103-10. 
16. Miteva M, Tosti A. Dermatoscopic features of central centrifugal cicatricial alopecia. J Am Acad 
Dermatol. 2014 Sep;71(3):443-9.  
17. Miteva M, Tosti A. Dermoscopy guided scalp biopsy in cicatricial alopecia. J Eur Acad Dermatol 
Venereol. 2013 Oct;27(10):1299-303 
18. Katoulis AC, Christodoulou C, Liakou AI, et al. Quality of life and psychosocial impact of 
scarring and non-scarring alopecia in women. JDDG: Journal der Deutschen Dermatologischen 
Gesellschaf. 2015;13:137–141.  
19. Zhang M, Zhang N. Quality of life assessment in patients with alopecia areata and androgenetic 
alopecia in the People’s Republic of China. Patient preference and adherence. 2017;11:151-155. 
doi:10.2147/PPA.S121218. 
 
 

SAP_001.pdf: 
An Open-label Pilot Study to Investigate the Efficacy of Apremilast in the Treatment of Central 
Centrifugal Cicatricial Alopecia (CCCA) Statistical Analysis Plan 
PI: Saakshi Khattri, MD  
NCT03521687  
Document Date: 04-05-2022 
 
 


Sample Size and Statistical Considerations 
 
 
A sample size of n=20 subjects and 3 experts provide 90% power at 5% significance to detect a 
pooled mean improvement in PGA-I of 0.8 units from baseline with the use of a one-sided paired 
t-test. Since changes in the outcome only take values in the interval between -3 and 3, our 
calculation assumes the maximum standard deviation (SD =1.15) for the pooled mean PGA-I 
change from baseline obtained from 3 expert dermatologists. Our power analysis approach is 
conservative as it ignores intra-subject correlation evaluated by different experts which might 
increase statistical power.    
 
Data Analysis 
 
At weeks 12 and 24 we will test for significant improvement in PGA-I and IGSS with one-sided 
paired t-tests, after pooling scores obtained from 3 dermatologists. We will apply Wilcoxon and 
Friedman’s nonparametric tests to CHLG, VAS, PaGA-I, and DLQI to compare scores between time 
points (baseline, weeks 12 and 24). An overview will be obtained by drawing a correlation map 
that clusters clinical outcomes based on the Spearman correlation coefficient. As a more 
comprehensive approach, and to better capture the dynamics of clinical outcomes over time, we 
will fit hierarchical ordinal regression models developed to handle ordinal and longitudinal 
responses. We will use the last observation carry-forward strategy to mitigate the impact of 
missing data.